$SPRO
Spero Therapeutics Inc

2021 Q3 Form 10-Q Financial Statement

#000095017021000924 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $3.064M $5.148M $1.727M
YoY Change -23.3% 198.09% -19.9%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.15M $9.229M $4.550M
YoY Change 110.02% 102.84% 20.37%
% of Gross Profit
Research & Development $14.44M $14.46M $15.66M
YoY Change -18.47% -7.63% 30.14%
% of Gross Profit
Depreciation & Amortization $148.0K $147.0K $190.0K
YoY Change -22.11% -22.63% 0.0%
% of Gross Profit
Operating Expenses $25.59M $23.69M $20.20M
YoY Change 11.18% 17.26% 27.8%
Operating Profit -$22.52M -$18.54M -$18.48M
YoY Change 18.42% 0.36% 35.34%
Interest Expense $90.00K $82.00K $90.00K
YoY Change 200.0% -8.89% -82.07%
% of Operating Profit
Other Income/Expense, Net $3.000K -$30.00K $975.0K
YoY Change -96.43% -103.08% 94.22%
Pretax Income -$22.52M -$18.57M -$17.50M
YoY Change 18.91% 6.13% 33.08%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$22.50M -$18.60M -$17.50M
YoY Change 19.05% 6.29% 32.58%
Net Earnings / Revenue -734.33% -361.31% -1013.32%
Basic Earnings Per Share -$0.70 -$0.63
Diluted Earnings Per Share -$700.9K -$0.63 -$848.3K
COMMON SHARES
Basic Shares Outstanding 32.15M 29.68M
Diluted Shares Outstanding 32.13M 29.68M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $123.4M $99.22M $71.40M
YoY Change -2.97% 38.96% -30.95%
Cash & Equivalents $112.9M $71.56M $65.34M
Short-Term Investments $10.56M $27.66M $6.000M
Other Short-Term Assets $5.768M $4.901M $7.200M
YoY Change 8.83% -31.93% 33.33%
Inventory
Prepaid Expenses
Receivables $2.000M
Other Receivables $4.800M
Total Short-Term Assets $131.8M $106.3M $85.30M
YoY Change -7.66% 24.64% -24.31%
LONG-TERM ASSETS
Property, Plant & Equipment $1.214M $1.362M $6.800M
YoY Change -86.8% -79.97% 152.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.212M $5.211M $5.078M
YoY Change 0.23% 2.62% 107.35%
Total Long-Term Assets $12.92M $13.28M $12.25M
YoY Change -9.64% 8.44% 24.96%
TOTAL ASSETS
Total Short-Term Assets $131.8M $106.3M $85.30M
Total Long-Term Assets $12.92M $13.28M $12.25M
Total Assets $144.7M $119.6M $97.55M
YoY Change -7.84% 22.6% -20.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.161M $1.632M $1.562M
YoY Change 26.44% 4.48% 50.34%
Accrued Expenses $12.40M $10.02M $17.50M
YoY Change -17.89% -42.77% 150.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.26M $12.83M $19.00M
YoY Change -1.73% -32.49% 130.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $15.54M $16.52M $4.800M
YoY Change 131.91% 244.08% 4.35%
Total Long-Term Liabilities $15.54M $16.52M $4.800M
YoY Change 131.91% 244.08% 4.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.26M $12.83M $19.00M
Total Long-Term Liabilities $15.54M $16.52M $4.800M
Total Liabilities $32.80M $29.34M $23.80M
YoY Change 34.96% 23.29% 85.65%
SHAREHOLDERS EQUITY
Retained Earnings -$338.2M -$315.7M -$240.2M
YoY Change 30.53% 31.43% 53.26%
Common Stock $450.1M $406.0M $313.9M
YoY Change 14.85% 29.34% 1651815.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $111.9M $90.25M $73.71M
YoY Change
Total Liabilities & Shareholders Equity $144.7M $119.6M $97.55M
YoY Change -7.86% 22.6% -20.37%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$22.50M -$18.60M -$17.50M
YoY Change 19.05% 6.29% 32.58%
Depreciation, Depletion And Amortization $148.0K $147.0K $190.0K
YoY Change -22.11% -22.63% 0.0%
Cash From Operating Activities -$4.952M -$16.57M -$24.90M
YoY Change -76.71% -33.47% 106.3%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0% -88.89%
Acquisitions
YoY Change
Other Investing Activities $17.03M $10.92M $18.50M
YoY Change 325.63% -40.96% -25.79%
Cash From Investing Activities $17.03M $10.92M $18.48M
YoY Change 331.01% -40.9% -25.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.22M 167.0K 7.390M
YoY Change -62.15% -97.74% -17.52%
NET CHANGE
Cash From Operating Activities -4.952M -16.57M -24.90M
Cash From Investing Activities 17.03M 10.92M 18.48M
Cash From Financing Activities 29.22M 167.0K 7.390M
Net Change In Cash 41.30M -5.477M 970.0K
YoY Change -31.06% -664.64% -95.54%
FREE CASH FLOW
Cash From Operating Activities -$4.952M -$16.57M -$24.90M
Capital Expenditures $0.00 $0.00 -$10.00K
Free Cash Flow -$4.952M -$16.57M -$24.89M
YoY Change -76.64% -33.44% 107.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
463627
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001701108
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38266
dei Entity Registrant Name
EntityRegistrantName
SPERO THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4590683
dei Entity Address Address Line1
EntityAddressAddressLine1
675 Massachusetts Avenue,
dei Entity Address Address Line2
EntityAddressAddressLine2
14th  Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
242-1600
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
SPRO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32146847
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71562000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85209000
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
27656000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
41697000
CY2021Q2 us-gaap Other Receivables
OtherReceivables
1851000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
5330000
CY2021Q2 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
346000
CY2020Q4 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
846000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4901000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6063000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
106316000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
139145000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1362000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1669000
CY2021Q2 spro Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
0
CY2020Q4 spro Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
311000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6705000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7114000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5211000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5212000
CY2021Q2 us-gaap Assets
Assets
119594000
CY2020Q4 us-gaap Assets
Assets
153451000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1632000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1155000
CY2021Q2 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9007000
CY2020Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12241000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1008000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
947000
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1179000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12826000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14343000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6430000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6891000
CY2021Q2 us-gaap Deferred Revenue
DeferredRevenue
9928000
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2021Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
158000
CY2020Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
177000
CY2021Q2 us-gaap Liabilities
Liabilities
29342000
CY2020Q4 us-gaap Liabilities
Liabilities
21411000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3218152
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3218152
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3218287
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3218287
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29699147
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29699147
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29260247
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29260247
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
30000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
405923000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
409722000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-315702000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277707000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
90252000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
132040000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119594000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153451000
CY2021Q2 spro Grant Revenue
GrantRevenue
3042000
CY2020Q2 spro Grant Revenue
GrantRevenue
1676000
spro Grant Revenue
GrantRevenue
10342000
spro Grant Revenue
GrantRevenue
3208000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2106000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2106000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
220000
CY2021Q2 us-gaap Revenues
Revenues
5148000
CY2020Q2 us-gaap Revenues
Revenues
1727000
us-gaap Revenues
Revenues
12448000
us-gaap Revenues
Revenues
3428000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14461000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15656000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32865000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36092000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9229000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4547000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8633000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
23690000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
20203000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17528000
us-gaap Operating Expenses
OperatingExpenses
50393000
us-gaap Operating Expenses
OperatingExpenses
44725000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18542000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18476000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37945000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41297000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
82000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
86000
us-gaap Investment Income Interest
InvestmentIncomeInterest
180000
us-gaap Investment Income Interest
InvestmentIncomeInterest
323000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-112000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
889000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-230000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
215000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
975000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-50000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
538000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-18572000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-17501000
us-gaap Profit Loss
ProfitLoss
-37995000
us-gaap Profit Loss
ProfitLoss
-40759000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.06
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29675399
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20633402
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29545496
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20095415
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-18572000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-17501000
us-gaap Profit Loss
ProfitLoss
-37995000
us-gaap Profit Loss
ProfitLoss
-40759000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
34000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
34000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18571000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17467000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37990000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40760000
us-gaap Profit Loss
ProfitLoss
-37995000
us-gaap Profit Loss
ProfitLoss
-40759000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
307000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
379000
spro Non Cash Lease Cost
NonCashLeaseCost
402000
spro Non Cash Lease Cost
NonCashLeaseCost
224000
us-gaap Share Based Compensation
ShareBasedCompensation
4172000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
808000
us-gaap Share Based Compensation
ShareBasedCompensation
2324000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
251000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-124000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
59000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-3479000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-3727000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1258000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4334000
spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
-800000
spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
252000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
8000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1761000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
478000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2567000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3314000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4857000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1356000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-19000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-53000
spro Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-400000
spro Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
14000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32046000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48225000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
12578000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3995000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
26500000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
50350000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
94000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13922000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
46261000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4253000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7271000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
146000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
502000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
370000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4477000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37576000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13647000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
35612000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
85209000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29730000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71562000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65342000
spro Offering And Financing Costs Included In Accounts Payable And Accrued Expenses
OfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
80000
CY2020 spro Offering And Financing Costs Included In Accounts Payable And Accrued Expenses
OfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
0
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-18572000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
90252000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
132040000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
118846000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
277000
CY2021Q2 spro Adjustments To Additional Paid In Capital Premium For Commitment To Sell Common Stock
AdjustmentsToAdditionalPaidInCapitalPremiumForCommitmentToSellCommonStock
12463000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2163000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
370000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4123000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4172000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5000
us-gaap Profit Loss
ProfitLoss
-37995000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
90252000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
82427000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
269000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7271000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1214000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
34000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-17501000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
73714000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
74574000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
808000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16226000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2324000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
us-gaap Profit Loss
ProfitLoss
-40759000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
73714000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18600000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-17500000
us-gaap Net Income Loss
NetIncomeLoss
-38000000.0
us-gaap Net Income Loss
NetIncomeLoss
-40800000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-315700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for clinical trial costs and other research and development expenses, and the valuation of share-based awards. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has contemplated the impact of COVID-19 within its financial statements and is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. There may be changes to those estimates in future periods. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk and of Significant Suppliers</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains most of its cash and cash equivalents at one accredited financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and December 31, 2020, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.</span><span style="font-size:10.0pt;font-family:Times New Roman;"/></span></p>
us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of June 30, 2021, and December 31, 2020, the Company had no off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.
CY2021Q2 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
CY2020Q4 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
spro Cares Act Percentage Of Bonus Depreciation
CARESActPercentageOfBonusDepreciation
1
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
700000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
2700000
CY2021Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
27658000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
spro Cares Act Eliminated Percentage On Limitation Of Taxable Income
CARESActEliminatedPercentageOnLimitationOfTaxableIncome
0.80
spro Cares Act Percentage Of Adjusted Taxable Income Plus Business Interest Income
CARESActPercentageOfAdjustedTaxableIncomePlusBusinessInterestIncome
0.50
spro Cares Act Percentage Of Limitation On Adjusted Taxable Income Plus Business Interest Income Under Tax Cut And Jobs Act2017
CARESActPercentageOfLimitationOnAdjustedTaxableIncomePlusBusinessInterestIncomeUnderTaxCutAndJobsAct2017
0.30
spro Cares Act Percentage Of Corporate Charitable Deduction Limitation On Taxable Income
CARESActPercentageOfCorporateCharitableDeductionLimitationOnTaxableIncome
0.25
spro Cares Act Eligible Cost Recovery Period
CARESActEligibleCostRecoveryPeriod
P15Y
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
27656000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
41703000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
41697000
CY2021Q2 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
4752000
CY2020Q4 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
7035000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2495000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3918000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1560000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1066000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
200000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
222000
CY2021Q2 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9007000
CY2020Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12241000
spro Number Of Equity Compensation Plans
NumberOfEquityCompensationPlans
2
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.70
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3682233
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.10
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M2D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37881000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1169615
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.28
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
46715
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
225425
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.83
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4579708
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M10D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17689000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
4579708
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M10D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
17689000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2260040
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y8M1D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
13066000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
5549873
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2163000
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1214000
us-gaap Share Based Compensation
ShareBasedCompensation
4172000
us-gaap Share Based Compensation
ShareBasedCompensation
2324000
spro Contract Term
ContractTerm
P2Y
us-gaap Separate Account Liability Premium
SeparateAccountLiabilityPremium
12500000
spro Performance Obligation Allocated Transaction Price
PerformanceObligationAllocatedTransactionPrice
12500
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-18572000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-17501000
us-gaap Profit Loss
ProfitLoss
-37995000
us-gaap Profit Loss
ProfitLoss
-40759000
CY2021Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
CY2020Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
549000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18572000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17501000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37995000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41308000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29675399
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20633402
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29545496
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20095415
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.06
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10946708
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8708761
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10946708
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8708761

Files In Submission

Name View Source Status
0000950170-21-000924-index-headers.html Edgar Link pending
0000950170-21-000924-index.html Edgar Link pending
0000950170-21-000924.txt Edgar Link pending
0000950170-21-000924-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img110152170_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spro-20210630.htm Edgar Link pending
spro-20210630.xsd Edgar Link pending
spro-20210630ex10_1.htm Edgar Link pending
spro-20210630ex10_2.htm Edgar Link pending
spro-20210630ex31_1.htm Edgar Link pending
spro-20210630ex31_2.htm Edgar Link pending
spro-20210630ex32.htm Edgar Link pending
spro-20210630_cal.xml Edgar Link unprocessable
spro-20210630_def.xml Edgar Link unprocessable
spro-20210630_htm.xml Edgar Link completed
spro-20210630_lab.xml Edgar Link unprocessable
spro-20210630_pre.xml Edgar Link unprocessable